Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

Overview

• In the randomized EPCORE FL-1 trial of 488 patients, adding epcoritamab to rituximab and lenalidomide cut the risk of progression or death by about 80%, with 16‑month progression‑free survival of 85.5% versus 40.2% with R2 alone.
• Overall response was 95.1% with the triplet versus 79.2% with R2, complete responses reached 82.7% versus 49.8%, and responses were deeper and more durable across all analyzed subgroups.
• Time off further therapy improved, with 92.8% of patients on the epcoritamab regimen remaining treatment‑free at 16 months compared with 64.9% on R2 alone.
• Grade 3–4 adverse events were more frequent with the triplet (90.1% vs 67.6%), driven by neutropenia and infections, while no grade 3–4 cytokine release syndrome or neurological toxicity was reported in the follow‑up period.
• The FDA cleared the epcoritamab–R2 regimen in November 2025 based on these data, which were published in The Lancet and presented at ASH, with ongoing follow‑up and frontline testing underway; the study was funded by Genmab and AbbVie.